Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-259-3860
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$380,000.00
Profitability
Miscellaneous
Employees65
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
How were Scholar Rock's earnings last quarter?
Scholar Rock Holding Corp (NASDAQ:SRRK) released its earnings results on Wednesday, August, 14th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.07. The company earned $5.04 million during the quarter, compared to the consensus estimate of $5.38 million. View Scholar Rock's Earnings History.
When is Scholar Rock's next earnings date?
What price target have analysts set for SRRK?
2 analysts have issued 1-year target prices for Scholar Rock's shares. Their forecasts range from $27.00 to $27.00. On average, they anticipate Scholar Rock's share price to reach $27.00 in the next year. This suggests a possible upside of 138.7% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
News stories about SRRK stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Scholar Rock earned a news impact score of -1.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Scholar Rock.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), NanoString Technologies (NSTG), Vericel (VCEL), Mesoblast (MESO), GENFIT S A/ADR (GNFT) and Voyager Therapeutics (VYGR).
What other stocks do shareholders of Scholar Rock own?
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 43)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)
- Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications
When did Scholar Rock IPO?
(SRRK) raised $76 million in an IPO on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Scholar Rock's major shareholders?
Scholar Rock's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.97%), BlackRock Inc. (3.44%), Vanguard Group Inc. (3.31%), Jefferies Group LLC (1.11%), Northern Trust Corp (0.66%) and CVI Holdings LLC (0.64%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View Institutional Ownership Trends for Scholar Rock.
Which major investors are selling Scholar Rock stock?
SRRK stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Victory Capital Management Inc., JPMorgan Chase & Co. and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Scholar Rock.
Which major investors are buying Scholar Rock stock?
SRRK stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Jefferies Group LLC, Vanguard Group Inc., CVI Holdings LLC, Marshall Wace North America L.P., Monashee Investment Management LLC, BlackRock Inc. and Alps Advisors Inc.. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat and International SCA Artal. View Insider Buying and Selling for Scholar Rock.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $11.31.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $335.68 million and generates $380,000.00 in revenue each year. The company earns $-49,330,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Scholar Rock employs 65 workers across the globe.View Additional Information About Scholar Rock.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
